National Institute of Allergy and Infectious Diseases (NIAID): Virus Diseases trials

The registry lists 44 Virus Diseases studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 6 are open to participants now and 9 have results posted.

Phase 1 27Phase 2 5Phase 3 5No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus InfectionRecruitingNCT07706686Phase 1
• Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 InfluenzaEnrolling by invitationNCT07215871Phase 1
• Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy AdultsRecruitingNCT06863142Phase 1
• Viral Infections in Healthy and Immunocompromised HostsRecruitingNCT01306084
• The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known ImmunocompromiseRecruitingNCT01011712
• Genetic Studies of Chronic Active Epstein-Barr DiseaseRecruitingNCT00032513
• Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729606Phase 3Results posted
• Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729593Phase 3Results posted
• A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult ParticipantsActive, not recruitingNCT05217641Phase 1Results posted
• ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedNCT04843761Phase 3Results posted
• Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of AgeTerminatedNCT03916185Phase 1/2Results posted
• Investigational Therapeutics for the Treatment of People With Ebola Virus DiseaseCompletedNCT03719586Phase 2/3Results posted
• cAd3-Marburg Vaccine in Healthy AdultsCompletedNCT03475056Phase 1Results posted
• VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and AdolescentsCompletedNCT03110770Phase 2Results posted
• Partnership for Research on Ebola VACcinationsCompletedNCT02876328Phase 2Results posted
• Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy AdultsCompletedNCT05968989Phase 1
• PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine ResponseCompletedNCT03098862
• Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima PeruCompletedNCT02630082Not applicable
• Ebola Virus Disease Survivors: Clinical and Immunologic Follow-upCompletedNCT02431923
• Phase 1 Trial of Inactivated West Nile Virus VaccineCompletedNCT02337868Phase 1
• Immunogenicity of Off-Schedule Dosing of HPV VaccineCompletedNCT01030562
• Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and ChildrenCompletedNCT01021397Phase 1
• Evaluating an Ebola and a Marburg Vaccine in UgandaCompletedNCT00997607Phase 1
• Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy AdultsCompletedNCT00921726Phase 1
• Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00853255Phase 1
• Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine VaccineCompletedNCT00734175Phase 1
• Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus VaccineCompletedNCT00722774Phase 1
• Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector InjectionCompletedNCT00709605Phase 1
• Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus VaccineCompletedNCT00641017Phase 1
• Ebola and Marburg Virus VaccinesCompletedNCT00605514Phase 1
• Influenza in People With Normal and Weakened Immune SystemsCompletedNCT00533182
• Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00516035Phase 1
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 1
• Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00488046Phase 1
• Safety Study of Avian Flu VaccineCompletedNCT00408109Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)CompletedNCT00380237Phase 1
• Experimental Vaccine for Prevention of Ebola Virus InfectionCompletedNCT00374309Phase 1
• Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and AdultsCompletedNCT00366782Phase 1
• Identification of Viruses Associated With Diseases of Unknown CauseTerminatedNCT00359268
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00347672Phase 1
• Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy InfantsCompletedNCT00308412Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)CompletedNCT00110279Phase 1
• Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant PatientsTerminatedNCT00031473Phase 3
• The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAUCompletedNCT00000654Phase 2